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BACKGROUND: A two-phase ‘respiratory symptoms’ mass media campaign was conducted in 2016 and 2017 in England raising
awareness of cough and worsening shortness of breath as symptoms warranting a general practitioner (GP) visit.
METHOD: A prospectively planned pre–post evaluation was done using routinely collected data on 15 metrics, including GP
attendance, GP referral, emergency presentations, cancers diagnosed (five metrics), cancer stage, investigations (two metrics),
outpatient attendances, inpatient admissions, major lung resections and 1-year survival. The primary analysis compared 2015 with
2017. Trends in metrics over the whole period were also considered. The effects of the campaign on awareness of lung cancer
symptoms were evaluated using bespoke surveys.
RESULTS: There were small favourable statistically significant and clinically important changes over 2 years in 11 of the 15 metrics
measured, including a 2.11% (95% confidence interval 1.02–3.20, p < 0.001) improvement in the percentage of lung cancers
diagnosed at an early stage. However, these changes were not accompanied by increases in GP attendances. Furthermore, the time
trends showed a gradual change in the metrics rather than steep changes occurring during or after the campaigns.
CONCLUSION: There were small positive changes in most metrics relating to lung cancer diagnosis after this campaign. However,
the pattern over time challenges whether the improvements are wholly attributable to the campaign. Given the importance of
education on cancer in its own right, raising awareness of symptoms should remain important. However further research is needed
to maximise the effect on health outcomes.
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01573-w
BACKGROUND
Lung cancer remains a very important health problem globally,
including the United Kingdom, where it represented 13% of newly
diagnosed cancers cases in 2016 [1]. It is the second most
common cancer in both genders and is the most common cause
of UK cancer death, with 18,810 men and 16,338 women dying
from it in 2017 [2]. Although there is evidence of steady
improvement over time, lung cancer survival remains poor,
particularly relative to the three other most common cancers [3].
Changes in lung cancer incidence over time are complex,
generally decreasing in men, but increasing in women, reflecting
historical smoking patterns. The expanding and ageing UK
population is predicted to increase lung cancer incidence, as it
is highly age-dependent. The net effect is that UK lung cancer
numbers are currently slowly increasing.
Survival in lung cancer is related to the stage at diagnosis. Stage
1 has a 5-year survival of 56.6%, whereas Stage 4 has a 5-year
survival of 2.9%. However, most lung cancers are present at Stage
4 [4]. Furthermore, one-third of lung cancers present as an
emergency, with the complication precipitating the emergency
presentation bringing additional mortality [5]. These facts suggest
an opportunity to improve the outcome of lung cancer by
identifying it earlier. Screening with low-dose computed tomo-
graphy (CT) currently shows great promise based on the USA [6]
and recent European trials [7–9].
Promoting public awareness of early symptoms is a further
secondary prevention approach. The rationale and general frame-
work for improving outcomes and advancing diagnosis in cancer are
laid out in the National Awareness and Early Diagnosis Initiative
(NAEDI) models [10, 11]. The theoretical model for lung cancer is
that patients would recognise symptoms of possible cancer earlier
(including symptoms previously considered as ‘normal’ for the
individual). The increased recognition might act during
the awareness campaign or for future symptoms. It may also be
mediated through the individuals’ families. Symptom recognition
would lead to attendance at primary care, which would investigate
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possible lung cancer. This pathway requires several steps to improve
outcomes. Individuals newly recognising the potential implications
of their symptoms must act by entering healthcare; general
practitioners (GPs) must be receptive to more patients presenting
with low-risk symptoms and there needs to be sufficient
investigative capacity in the health system to accommodate
increased numbers in a timely fashion. This expedited process
may improve outcomes through stage shift, plus by a reduction in
emergency presentation, independent of any stage shift.
In 2012 the first national (England) public awareness campaign
relating to possible lung cancer focused on the symptom of cough
persisting for more than 3 weeks. It followed a successful regional
pilot and was evaluated by comparing metrics during and
immediately after the 8-week mass media campaign with the
same period a year before [12]. The secular change was estimated
by considering the change in a ‘control’ period, immediately
before the mass media campaign, with the same period a year
before. The 3-monthly lung cancer incidence increased by 9.1% in
the ‘campaign’ 1-year pre–post change, but only by 1.5% for the
‘control’ 1-year pre–post change. A stage shift was identified, with
an increase in Stage 1 and a fall in Stage 4 at diagnosis in the
‘campaign’ 1-year pre–post change. There was a consistent
pattern of changes in other metrics favouring a positive impact
of the campaign, including increased awareness of lung cancer
symptoms, presentations to primary care, GP referrals for imaging
and GP referrals for suspected cancer. These led to the conclusion
that the campaign had been effective.
Based on the effectiveness of the 2012 campaign, a further
campaign was planned for 2016 and 2017, modified to include
shortness of breath as well as cough, with the intention of
improving identification of not just lung cancer but other serious
respiratory and cardiovascular disease too. An evaluation similar to
that for the cough-only campaigns was pre-planned and led by an
independent team who finalised the analytical framework. This
paper reports this evaluation.
MATERIALS AND METHODS
The ‘campaign’ was part of the Be Clear on Cancer programme, led by
Public Health England, aiming to improve the early diagnosis of cancer by
raising public awareness of symptoms and signs of cancer and
encouraging people to attend their GP without delay. The national mass
media campaign ran across England from 14 July 2016 to 16 October 2016
(Phase 1) [13 weeks] and from 18 May 2017 to 31 August 2017 (Phase 2)
[16 weeks] using the ‘Be Clear on Cancer’ brand with the core messages:
If you’ve had a cough for three weeks or more, it could be a sign of
lung disease, including cancer. Finding it early makes it more treatable.
So don’t ignore it, tell your doctor.
and
If you get out of breath doing things you used to be able to do, it could
be a sign of lung or heart disease, or even cancer. Finding it early
makes it more treatable. So don’t ignore it, tell your doctor.
The campaign activity was aimed at men and women aged 50 years and
over. The ‘Be Clear on Cancer’ website provides more detail [13].
Data collection and analysis
Data were collected and analysed for the set of metrics described below, to
represent the patient pathway from symptom awareness, through to
diagnosis, stage, treatment and survival. The main analyses explored
changes in metrics following the campaign launch, by considering Phase 1
(in 2016) and Phase 2 (2017) as a single campaign, comparing the period
during and shortly after Phase 2 (analysis period), to the equivalent period
before Phase 1 (comparison period). Further analyses explored changes in
metrics following the launch of Phase 1 of the campaign, by comparing the
period during and shortly after Phase 1 (analysis period), to the equivalent
period before Phase 1 (comparison period). The exact time periods varied
slightly across metrics accommodating the expectation that each metric
would be impacted at different times (e.g. GP attendances should change
very soon after the start of the campaign, whereas cancer diagnoses would
change after a few weeks). The analysis and comparison periods used for
each metric are detailed in Table 1.
Awareness of lung cancer symptoms. Responses to key questions relating to
the campaign’s core messages were obtained through surveys conducted by
an independent organisation immediately before, during and immediately
after each of the two phases of the campaign. Only the results pre the first
phase and post the second were used in our analysis. Surveys were
conducted online in those aged 50–69 years and face to face in those aged
70+ years in 2017; 2016 data were adjusted post hoc to mirror this pattern,
ignoring data collected face to face on those aged 50–69 years. Data
collected were combined and weighted to be nationally representative on
the basis of age, gender, socioeconomic status and geographic region. The
questions deemed most relevant to the linkage between awareness and
likelihood of action were the focus of the analysis, which compared before
Phase 1 (24 June 2016 to 5 July 2016) with the end of Phase 2 (19 September
2017 to 2 October 2017). The complete survey was an extensive examination
of the effectiveness of the campaign in meeting its stated objectives. It
included questions on reaction to breathlessness or persistent cough
symptoms; agreement of symptoms being a sign of something more
serious; recent exposure to adverts, publicity or other types of information;
the meaning of breathlessness or persistent cough; agreement with
statements on various health conditions; reasons for putting off going to
see the GP/doctor; agreement with statements concerning doctor waste of
time/judgement/worry; agreement with statements about the advertising;
recognition of aspects of the campaign; knowledge of persons with heart
and lung conditions; and aspects of health and lifestyle.
GP attendances. Data on GP attendances by those aged 50 years and
above for respiratory symptoms (cough, breathlessness, other respiratory
symptoms) were sourced from The Health Improvement Network (THIN)
[14]. Data were grouped into weeks and adjusted to account for bank
holidays.
Urgent GP referrals for suspected lung cancer (2-week wait (TWW) referrals)
and cancers diagnosed from TWW referral. Data on GP referrals for
suspected lung cancer, new lung cancer cases that resulted from a TWW
referral and the percentage of TWW referrals resulting in a diagnosis of
lung cancer (conversion rate) were sourced from the National Cancer
Waiting Times Monitoring Dataset [15]. Data were monthly, with referrals
and diagnoses reported in the month that the patient was first seen. Lung
cancers were defined as an International Statistical Classification of
Diseases and Related Health Problems 10th Revision (ICD-10) diagnosis
code of C33-C34, C37-C39 or C45.
Cancer diagnoses recorded in the cancer waiting time (CWT) database. Data
on the number of lung cancer diagnoses recorded in the CWT database
and on the percentage of new CWT database recorded lung cancer
diagnoses, which resulted from a TWW referral (detection rate), were taken
from the National Cancer Waiting Times Monitoring Dataset [15]. Data
were monthly and diagnoses were reported in the month of first
treatment. Lung cancer cases were defined as those with an ICD-10
diagnosis code of C33-C34, C37-C39 or C45.
Emergency presentations. The Hospital Episode Statistics (HES) emergency
presentation metric was calculated from inpatient data, using the
methodology set out in the cancer outcomes metric specification [16].
We report monthly percentages of lung cancer diagnoses first presenting
as an emergency.
Cancers diagnosed and early stage at diagnosis. Data on the weekly
number of newly diagnosed cases of lung cancer (ICD-10 of C33-34) were
extracted from the National Cancer Registration Dataset in England [17]. Of
those cases that were staged, the weekly percentages of early-stage
(Stages 1, 2 and 3a) cases were calculated.
Diagnostics in secondary care. Data on the monthly number of X-ray and
CT scans conducted for suspected lung cancer by GPs were obtained from
the Diagnostic Imaging Dataset held on the NHS Digital’s iView system.
Data were restricted to X-ray and CT scans referred via GP surgeries.
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Echocardiograms. Data on the monthly number of echocardiograms
performed were sourced from the NHS Monthly Diagnostic Waiting Times
and Activity dataset [18].
Outpatient attendances and inpatient admissions. Data on weekly
numbers of outpatient attendances seen under cardiac and respiratory
services (cardiology, respiratory and general medicine) and on weekly
numbers of inpatient admissions with either heart failure, chronic
obstructive pulmonary disease or dyspnoea were taken from the HES
dataset.
Major resections for lung cancer. Data were extracted from the National
Cancer Registration Dataset in England. Monthly percentages of patients
with lung cancer who had a major resection within 6 months of their
diagnosis were calculated.
Survival. Data on the time to death or last follow-up (up to 1 year) of
patients diagnosed with lung cancer during the analysis and comparison
periods were provided by NHS Digital, in cohorts defined using the
National Cancer Registration Dataset.
Analysis: For survey questions relating to an agreement of symptoms
being a sign of something more serious, the percentages of respondents
answering ‘agree strongly’ or ‘agree’, from possible response options of
‘agree strongly’, ‘agree’, ‘disagree’, ‘disagree strongly’ and ‘don’t know’,
were compared between analysis and comparison periods using the two-
sample test of proportions. Similarly, the percentages of respondents
answering that they would visit their GP if they were breathless doing
things they could usually do, and if they had a cough lasting 3 weeks or
longer, were compared between periods. Results are reported as numbers
and percentages in each period and the absolute difference in percentages
between the two periods, with 95% confidence interval (CI) and p value.
Where metrics were measured using weekly or monthly percentages,
these were aggregated over the analysis and comparison periods to give a
single percentage for each period, and the two-sample test of proportions
was used to test for any difference between the periods. Results are
reported as numbers and percentages in each period and the absolute
difference in percentages between the two periods, with 95% CI and p
value. Where data were weekly or monthly counts, these were compared
using negative binomial or Poisson regression, with a single explanatory
variable coded as 0 and 1 for the comparison and analysis period. For GP
attendances, the number of practices associated with weekly numbers of
attendances was included as an exposure in the fitted model. Results are
reported as the total count in each period and the estimated rate ratio
(analysis period relative to comparison period), with 95% CI and p value.
Survival data were compared using Cox regression, with time to death or
end of follow-up (1 year) as the outcome, and reported as median survival
and the estimated hazard ratio (analysis period relative to comparison
period), with 95% CI and p value.
Analyses were based on people of all ages, except for GP attendances
and survival, which used people aged ≥50 years. As <5% of lung cancers
are diagnosed below the age of 50 years, this decision (for operational
reasons) will have made no important difference to the results. For metrics
where the main analysis used data on people of all ages, sensitivity
analyses examined those aged ≥50 years, where possible.
Weekly or monthly data for the 3-year period 2015–2017 were graphed
and examined qualitatively for evidence of phasic changes occurring after
either or both of the two phases of the campaign.
All tests were conducted under a two-sided approach, with no
adjustment for multiple testing. Analyses were carried out in Stata 16
[19] and R [20].
RESULTS
Results from the analyses of survey questions used to assess
awareness of lung cancer symptoms are presented in Table 2.
There was an increase in awareness of symptoms targeted by
the campaign: getting out of breath (difference in the percentage
of respondents answering ‘agree strongly’ or ‘agree’ (analysis -
comparison period) 5.1%, 95% CI 1.3–8.9); coughing regularly for
3 weeks (difference in percentage answering ‘agree strongly’ or
‘agree’ (analysis - comparison period) 6.5%, 95% CI 3.1–9.9). There
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coughing up blood, which was not a target of the campaign
(difference in percentage (analysis - comparison period) 6.9%, 95%
CI 3.9–10.0). However, there was a fall in the likelihood of the
respondents saying they would visit their GP if these symptoms
did occur: getting out of breath (difference in percentage
(analysis - comparison period) −8.0%, 95% CI −12.6 to −3.3);
coughing lasting 3 weeks or more (difference in percentage
−7.2%, 95% CI −11.4 to −2.9).
Results from the main analyses of the routine data are detailed in
Table 3. All changes refer to the period of the second phase of the
campaign, compared to the same period before the first phase.
GP attendances
The rate of presentations to GPs of patients aged ≥50 for
respiratory symptoms was 4% lower (estimated rate ratio 0.96,
95% CI 0.90–1.03). Supplementary Fig. S1 confirms there was no
upturn in attendances during the phases of the campaign.
Urgent GP referrals for suspected lung cancer (TWW referrals)
There was an increase in urgent GP referrals for suspected lung
cancer (estimated rate ratio 1.10, 95% CI 1.02–1.19). However,
Supplementary Fig. S2 shows that this increase was not focused
on the phases of the campaign. There was little evidence of a
difference in the rate of cancer diagnoses resulting from a TWW
referral (estimated rate ratio 1.01, 95% CI 0.95–1.07). The
conversion rate decreased by 1.56% (95% CI −2.23 to −0.90).
Cancer diagnoses recorded in the CWT database
The number of lung cancer diagnoses recorded in the CWT
database increased (estimated rate ratio 1.07, 95% CI 1.01–1.13),
although the percentage of recorded lung cancer diagnoses,
which resulted from a TWW referral (detection rate), decreased by
3.9% (95% CI −5.1 to −2.7).
Emergency presentations
The percentage of lung cancer diagnoses that first presented as an
emergency was 1.48% lower (95% CI −2.63 to −0.34).
Cancers diagnosed and early stage at diagnosis
The rate of lung cancers diagnosed was 4% higher (estimated rate
ratio 1.04, 95% CI 1.01–1.06). The percentage of early stage at
diagnosis also increased by 2.11% (95% CI 1.02–3.2).
X-rays and CT scans and echocardiograms
The rate of imaging (X-ray or CT) and echocardiograms increased
by 14% (estimated rate ratio 1.14, 95% CI 1.06–1.22) and 11%
(estimated rate ratio 1.11, 95% CI 1.05–1.18), respectively.
Outpatient attendances and inpatient admissions
The rate of outpatient attendances and inpatient admissions
increased by 6% (estimated rate ratio 1.06, 95% CI 1.04–1.08) and
10% (estimated rate ratio 1.10, 95% CI 1.06–1.14), respectively.
Major resections
The percentage of lung cancer diagnoses that resulted in a major
resection was 1.95% higher (95% CI 1.15–2.76).
Survival
The median survival was 231 and 217 days for patients diagnosed
in the analysis and comparison period, respectively (HR 0.95, 95%
CI 0.92–0.98, p < 0.001).
Further analyses
The pattern of results was similar for the impact of Phase 1 alone
(see Supplementary Table 1).
Results for sensitivity analyses based on people aged ≥50 years
for the main and further analyses of were also similar to those for
the analyses based on people of all ages (see Supplementary
Tables 2 and 3).
Trends
In general, apart from considerable background variability in many
of the metrics, including pronounced seasonal effects, there were
no consistent phasic patterns suggesting changes during or after
each of the two phases of the campaign. The graphs suggest that
the changes observed between pre and post the campaign were
likely to be part of an underlying gradual trend (see Fig. 1 and
Supplementary Figs. 1–10).
DISCUSSION
The main findings are of small favourable statistically significant
and clinically important changes over 2 years, from before the first
phase of the campaign to after the second phase of it in 11 of the
15 metrics measured. For instance, the percentage of lung cancers
Phase 1 Phase 2
Comparison period Analysis period




















































Fig. 1 Emergency presentations. Monthly percentages of lung cancer diagnoses that first presented as an emergency, for the 3-year period
(2015–2017).
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presenting as an emergency fell by 1.48% (95% CI 2.63–0.34) and
the percentage of cancers that were diagnosed at an early stage
increased by 2.11% (95% CI 1.02–3.20). These are two key
outcomes that underpin the improvement in median survival,
with a hazard ratio of 0.95 (95% CI 0.92–0.98).
The four metrics that did not show this pattern were: the
number of respiratory 2-week wait referrals, where there was an
insignificant increase; GP attendances with a respiratory symptom
that fell, although insignificantly (rate ratio 0.96; 95% CI 0.90–1.03);
TWW referrals resulting in a cancer diagnosis (conversion rate: %),
which fell statistically significantly; and cancers diagnosed
recorded in CWT database from TWW referral (detection rate:
%), which also fell statistically significantly. The time trends
showed a gradual change in the metrics, rather than greater
changes occurring during or after the campaign phases. The
resulting profile was similar in the secondary and sensitivity
analyses.
There was improved awareness of the key target symptoms in
the surveys. However, there was also a fall in the percentages
saying they would visit their GP if either of the target symptoms,
cough for more than 3 weeks or shortness of breath, occurred.
This last item is discordant with the other positive metrics.
The study has strengths and weaknesses. It benefits from
being designed prospectively, with careful consideration of the
nature and timing of the data collected. It also allowed for the
campaign to be carefully described, particularly when it
commenced and stopped. The metrics used (excluding aware-
ness of lung cancer symptoms) were consistent throughout the
period of observation, and their routine nature protected
against manipulation. Data quality from our several sources is
considered to be high, including Cancer Waiting Times, cancer
registry data and the THIN primary care database [21, 22].
Furthermore, the analysis, including the development of an
analysis plan, was undertaken by an academic group, indepen-
dent of the group responsible for the campaign. The analysis
considered both the detailed trends over time and specific
pre–post comparisons, with specific time-points chosen to
account for a lesser/greater delay between the campaign and
change in some metrics. We do acknowledge that most metrics
were targeted at measuring the impact on lung cancer and so
may not have fully captured any effect on other respiratory and
cardiovascular diseases.
Data on awareness from the survey were arguably more open
to bias than the routine data. Differences in the survey method
between the 50–69 and the 70+ year age groups (online and
face to face, respectively) increased the complexity of inter-
pretation, accentuated further by data from 2016 face-to-face
surveys having to be omitted from the analysis in order to make
the survey methods consistent between 2016 and 2017.
Furthermore, the surveys are perforce hypothetical, whereas
all other metrics measured actual interaction with healthcare.
On balance, we did not feel these compromised validity greatly,
particularly as our conclusions did not rely on the survey results
alone, with the downstream metrics supporting diagnostic
improvements. Another important limitation is the design
cannot differentiate the effects of the campaign from other
changes occurring during the period of observation. Other
initiatives to expedite diagnosis of cancer in symptomatic
patients operated in England over the campaign, including
initiatives encouraging GPs to investigate more, notably the
NICE guidance published in June 2015 [23]. The continuing
upward trend in lung cancer incidence itself could have
contributed to changes and there are general upward trends
in 2-week referral waits for cancer [24]. Overdiagnosis is a
concern for lung cancer screening [25], raising the possibility
that not all lung cancers identified may have been the cause of
the symptoms. This ‘serendipitous’ percentage is estimated to
be 27–48% [26].
Concerning other evaluations, Ironmonger et al. remain the
main published evaluation of a national mass media cancer
symptom awareness campaign, describing the first campaign for
cough alerting to lung cancer in England, which ran in 2012 [12]. It
was widely deemed to have been effective, although less so when
the cough campaign was repeated in 2013 and 2014 [27]. Similar
metrics were measured to here, but with a striking difference in an
increase in GP attendances for cough in those aged >50 of 63%. It
is interesting also that the 1-year 1.5% increase in cancer
diagnoses in the ‘control’ period in Ironmonger et al. is similar
to the 2-year 4% increase in this study and that both are very
different from the 1-year 9.1% increase for the 2012 ‘campaign’
period. Other evaluations of local campaigns around the first
national cough campaign have reported positive results [28, 29].
These combined public awareness campaigns with brief interven-
tion GP training. Finally, an evaluation of a 4-week national
campaign in Wales in 2016 at the same time as the first phase of
the English campaign reported here showed improvements in
awareness and attitudes with statistically significant increases in
GP visits and GP-ordered chest X-rays, but without
statistically significant changes in urgent referrals or lung cancer
diagnoses [30].
This evidence offers a picture of varying effectiveness. All
campaigns achieved their immediate objective of increasing
awareness, but only some achieved directly attributable change
in downstream healthcare metrics. It is tempting to dismiss this as
merely the effect of the duration and intensity of the campaigns,
but this view is challenged by the campaign we report here being
longer than the 2012 campaign, which produced a positive effect
on outcomes. Differences in the precise nature of the campaigns
are likely to be important; for instance, the extension of the
campaign beyond promoting referral for lung cancer alone to
promoting referral for other serious diseases by the inclusion of
shortness of breath as a symptom. The effect of national mass
media cancer symptom awareness campaigns on health out-
comes is a complex interaction with activity in other parts of the
health service and the true complexity of this may not yet be fully
understood. One particular aspect is the interaction between
public awareness and primary care attendance, such as a partial
failure of increased awareness to translate into increased
attendances. A perceived lack of capacity may inhibit patients
presenting to primary care, and although they may still engage
with the health service via other routes, these are unlikely to be
able to request a chest X-ray.
In conclusion, our pre–post study of a national mass media
cancer awareness campaign targeting respiratory symptoms
showed small positive results in the metrics most linked to
survival—and in survival itself. A 2.11% improvement in early
stage at diagnosis approximates to 1000 UK lung cancer sufferers
becoming potentially curable each year and aligns well with the
aspiration in the NHS Ten Year Plan to increase early stage at
diagnosis. A benefit of this size suggests the BCOC campaign was
a ‘success’—although this needs to be balanced against some
uncertainty whether the changes can be wholly attributed to the
campaign itself. The pattern over time challenges whether the
improvements are attributable to the campaign. Greater changes
relative to the background trend/pattern would have been
expected in and around the campaign phases if this were the
case, particularly on metrics like GP attendance and referrals, and
this was not observed. Given the importance of education on
cancer in its own right, raising awareness of cancer symptoms
should remain an important approach. We need a better
understanding of the interplay between public awareness and
how that is translated into action (or not) by patients, GPs,
specialists and the healthcare system. Redesign of campaigns [31],
integration of them with other interventions [27], using different
interventions to encourage appropriate response to possible lung
cancer symptoms [32] and targeting activity to particular groups
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[33, 34] could all be more rationally deployed to maximise
effectiveness and cost-effectiveness if there were a better
theoretical model of action building on the updated NAEDI
model [11].
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